Search | Clinical Trials Finder

Conditions: End Stage Renal Disease
Interventions: there is no intervention; Other
Lead sponsor: Children's National Research Institute; Other
Eligibility: 3 Years to 21 Years
Enrollment: 150 participants
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Adenovirus Infection, EBV Infection
Interventions: Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 8
States / cities: Los Angeles, California • Coral Gables, Florida • Boston, Massachusetts + 3 more

Conditions: Cystic Fibrosis (CF)
Interventions: Elexacaftor / Ivacaftor / Tezacaftor, therapeutic drug monitoring; Drug · Other
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 3 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Seattle, Washington

Conditions: Diabetes Mellitus, Type 1
Interventions: Type One Training (TOT); Behavioral
Lead sponsor: Randi Streisand; Other
Eligibility: 21 Years to 99 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Neuroblastoma
Interventions: Interleukin-2; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2007
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Sickle Cell Disease, Asthma, Acute Chest Syndrome
Interventions: Budesonide inhalation suspension; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 1 Year to 4 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Congenital Heart Disease, Cardiovascular Disease
Interventions: Not listed
Lead sponsor: Children's National Research Institute; Other
Eligibility: Not listed
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Leukemia, Myelocytic, Acute
Interventions: Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 8
States / cities: Palo Alto, California • Boston, Massachusetts • Detroit, Michigan + 4 more

Conditions: Insulin Resistance, Obesity
Interventions: Aerobic exercise; Procedure
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 14 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Congenital Heart Disease in Children
Interventions: No intervention. It is observational; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 9
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more

Conditions: Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Interventions: Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution; Other
Lead sponsor: University of Calgary; Other
Eligibility: 9 Months to 21 Years
Enrollment: 1,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 22
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more

Conditions: Epilepsy in Children, Epilepsy in Youth, Randomized Controlled Trial, Refractory Epilepsy, Diet Intervention
Interventions: Low Glutamate diet; Other
Lead sponsor: American University; Other
Eligibility: 2 Years to 21 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Proteus Syndrome, PIK3CA Related Overgrowth Spectrum
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 1 Month to 99 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1994
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Epilepsy, Adherence, Medication
Interventions: Automated Digital Reminders, Individualized Adherence Feedback Report, Individual Adherence Feedback Report with Social Norms; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 13 Years to 17 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Asthma
Interventions: Emergency Department based asthma follow-up clinic; Behavioral
Lead sponsor: Stephen J. Teach, MD, MPH; Other
Eligibility: 12 Months to 17 Years
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Rhabdomyolysis
Interventions: Dexamethasone, Placebo; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 6 Months to 25 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Premature Neonates
Interventions: Morphine; Drug
Lead sponsor: John van den Anker; Other
Eligibility: 22 Weeks to 32 Weeks
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Smoking Cessation
Interventions: Counselor-Initiated Tobacco Quit Line, Self-Paced Tobacco Quit Line; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years and older
Enrollment: 946 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Craniofacial Microsomia, Hemifacial Microsomia, Oculo-Auriculo-Vertebral-Syndrome, Goldenhar Syndrome, Microtia
Interventions: Not listed
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 12 Months to 24 Months
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • Chapel Hill, North Carolina + 2 more

Conditions: Rett Syndrome, MECP2 Duplication Disorder, Rett-related Disorder
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 11
States / cities: Birmingham, Alabama • Oakland, California • San Diego, California + 8 more

Conditions: HIV Infections
Interventions: Needs assessment followed by tailored intervention; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 5 Years to 12 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • The Bronx, New York

Conditions: Palliative Care Education
Interventions: Rotation Using Flexible Education Tool, Standard Palliative Care Education; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Health Behavior
Interventions: Reduce Infant Mortality; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hemochromatosis, Cerebrovascular Accident, Anemia, Sickle Cell, Hematologic Diseases
Interventions: Red Cell Transfusions, Iron Chelation, Hydroxyurea, Phlebotomy; Procedure · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years to 18 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 28
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Jacksonville, Florida + 23 more

Search by objective public record fields.

Central Blood Pressure and Pulse Wave Velocity in Kidney Transplant Recipients

Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)

Ensuring Access to Optimal Therapy in CF: The ENACT Study

Healthy Eating, Physical Activity, and Glycemic Control in Young Children With T1D

Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma

Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial

Technical Development for Pediatric Cardiovascular MRI

Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia

An Exercise Intervention Study in Insulin-Resistant Adolescents

Outcomes and Health Care Resource Utilization in Pediatric Congenital Heart Disease Patients Undergoing Non-Cardiac Procedures

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

The Potential of a Low Glutamate Diet as a Treatment for Pediatric Epilepsy

Study of Proteus Syndrome and Related Congenital Disorders

Behavioral Economics and Adherence in Teens (BEAT!)

Improving Asthma Outcomes in an Urban Pediatric Population

Dexamethasone Use in Pediatric Rhabdomyolysis Patients in Addition to Standard Protocols

Optimizing the Use of Morphine in Pre-Term Neonates

Efficacy of Tobacco Quitline for Cancer Survivors

Craniofacial Microsomia: Longitudinal Outcomes in Children Pre-Kindergarten (CLOCK)

Genetic and Physical Characteristics of Rett Syndrome

Pediatric Impact: Promoting Adherence to Medications Among HIV-infected Children

Creating a Flexible Curriculum Tool for Pediatric Palliative Care Rotating Learners

Reduce African-American Infant Mortality

Stroke With Transfusions Changing to Hydroxyurea